769 patents
Page 5 of 39
Utility
Treatment of Food Allergy Using Anti-ige Antibodies
20 Jul 23
The present disclosure relates to methods for modifying the course of a disease or disorder involving IgE, in particular an IgE mediated food allergy to one or more allergens, in subjects having such disease or condition.
BOTTOLI Ivan, Maciej CABANSKI, Anna EGGER, Aurelie GAUTIER, Fernando Takeshi KAWAKAMI, Volkan MANGA
Filed: 14 Jun 21
Utility
Solid Forms Comprising an Oxime Ether Compound, Compositions and Methods of Use Thereof
13 Jul 23
Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
Lianfeng HUANG, Daozhong ZOU
Filed: 17 Mar 23
Utility
Therapeutic Fusion Proteins
13 Jul 23
The present invention relates to fusion proteins suitable for use as a medicament or research tool.
Sebastien IRIGARAY, Laurent KLEIN, Darko SKEGRO, Marco VILLANI, Karl WELZENBACH
Filed: 4 Sep 20
Utility
Treatment of Cancer Using a CD123 Chimeric Antigen Receptor
13 Jul 23
The invention provides compositions and methods for treating diseases associated with expression of CD123.
Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
Filed: 30 Dec 22
Utility
Dosing of Polyomavirus Neutralizing Antibodies
13 Jul 23
Provided are dosing regimens of polyomavirus neutralizing antibodies and related methods and pharmaceutical compositions for treating polyomavirus infections.
Johanna R. ABEND, Mark KNAPP, Steven J. KOVACS, Amy K. PATICK, Elisabetta TRAGGIAI
Filed: 9 Dec 22
Utility
IL-1BETA Binding Antibodies for Use In Treating Cancer
13 Jul 23
Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis.
Monica LIGUEROS-SAYLAN, Patrice MATCHABA, Tom THUREN, Paul RIDKER, Peter LIBBY, Penelope OTTEWELL, Yang Yi LAU, Margaret DUGAN
Filed: 22 Jun 18
Utility
2-AZASPIRO[3.4]OCTANE Derivatives As M4 Agonists
6 Jul 23
Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
Filed: 6 Dec 22
Utility
Sustained Release Delivery Systems Comprising Traceless Linkers
29 Jun 23
Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.
Christopher M. ADAMS, Myriam APRIL, Tanzina FAZAL, Cornelia Jutta FORSTER, Edward Charles HALL, Cameron Chuck-munn LEE
Filed: 11 Nov 22
Utility
Naphthyridinone Derivatives for the Treatment of a Disease or Disorder
29 Jun 23
Atwood Kim CHEUNG, Donglei LIU, Stefan PEUKERT, Heng GE, Yu GAI, Xingjuan CHANG
Filed: 21 Nov 22
Utility
Methods For Prevention Of Graft Rejection In Xenotransplantation
29 Jun 23
The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.
Guido JUNGE, James RUSH, Andrew B. ADAMS, Alfred Joseph TECTOR, III
Filed: 16 Sep 22
Utility
a Computer-implemented System and Method for Assessing a Level of Activity of a Disease or Condition In a Patient's Eye
25 May 23
The present invention relates to computer-implemented method for assessing a level of activity, including presence or an absence, of a disease in at least one eye of a patient, wherein the disease is a neovascular ocular disease.
Hsun-Hsien Shane CHANG, Daniel François Claude Lorand, Zufar MULYUKOV
Filed: 26 Apr 21
Utility
Methods of Selecting a Treatment for Cancer Patients
25 May 23
The disclosure is directed to novel predictive methods and personalized therapies for treating a patient with cancer such as breast cancer.
Fei SU, Marie-Caroline GERMA, Michelle MILLER, Wei HE
Filed: 21 Aug 18
Utility
OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG
18 May 23
Ofatumumab may be used in treating multiple sclerosis (MS), wherein the treatment is a long-term treatment and wherein serum IgG level is maintained during the treatment.
Ratnakar PINGILI, Martin MERSCHHEMKE
Filed: 9 Apr 21
Utility
Injection Device and Injection Solution Transferring System
18 May 23
An injection device (10) comprises an injection solution receptacle (30) and a plunger (70) at feast a portion of which is slidably received in the injection solution receptacle (30), wherein the plunger (70) is displaceable relative to the injection solution receptacle (30) in a distal direction in order to expel an injection solution contained in the injection solution receptacle (30) from the injection solution receptacle (30).
Nicholas Lee HAWSON, Martin MURPHY, Frederick William HAMLIN, Christophe ROYER, Dominic LLOYD-LUCAS, Tony BEDFORD, Andrew GOW, Dave HARRIS, Duncan Aleck BISHOP, Matthew GARWOOD, Matthew MURCHIE, Lasse MOGENSEN
Filed: 17 Jan 23
Utility
Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
4 May 23
The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations.
Joseph Paul BULLOCK, Chinmay MAHESHWARI, Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Kalliopi STASI
Filed: 8 Sep 22
Utility
Car T Cell Therapies with Enhanced Efficacy
4 May 23
The invention provides compositions and methods improved CAR T cell therapies.
Gregory Motz, Frederic Dixon Bushman, Joseph A. Fraietta, Carl H. June, Jan J. Melenhorst, Christopher Loren Nobles, Regina M. Young
Filed: 20 Sep 22
Utility
Lipoic Acid Choline Ester Compositions and Methods to Stabilize into Pharmaceutically Relevant Drug Products
4 May 23
The present invention describes ophthalmic lipoic acid choline ester compositions and specific processes to produce biocompatible formulations of said compositions suitable for the eye.
Shikha BARMAN, Koushik BARMAN, William BURNS, Kathryn CRAWFORD, Anne-Maria CROMWICK, Kevin WARD
Filed: 22 Sep 17
Utility
Bispecific Combination Therapy for Treating Proliferative Diseases and Autoimmune Diseases
27 Apr 23
The present disclosure provides methods of treating a subject having a proliferative disease or an autoimmune disorder with a combination of (a) a first multispecific binding molecule (MBM) that binds specifically to (i) human CD2 and (ii) a human tumor-associated antigen and/or a human tumor microenvironment antigen, and (b) a second multispecific binding molecule that binds specifically to (i) a component of a human T-cell receptor (TCR) complex or a secondary T-cell signaling molecule and (ii) a human tumor-associated antigen and/or human tumor microenvironment antigen.
Carl Uli BIALUCHA, Brian GRANDA
Filed: 26 Mar 21
Utility
Purification of Recombinantly Produced Polypeptides
27 Apr 23
The present invention relates generally to processes for production of heavily glycosylated recombinant proteins (e.g., mucins and mucin-like proteins, such as lubricin), the processes comprising culturing mammalian cells capable of producing a glycoprotein in a liquid medium in a system comprising one or more bioreactors, concentrating and purifying and formulating the glycoprotein, the purification comprising one or more steps of chromatography, an endonuclease step, and at least one step of viral inactivation.
Anne-Sophie BLUEMMEL, Hervé MOEBEL, Anders Klas PALM, Isabelle SAVOY, Henry STOSCH
Filed: 22 Feb 21
Utility
MLL1 Inhibitors and Anti-cancer Agents
20 Apr 23
Zhenting GAO, Haibing GUO, Ming LI, Kun Chin LIU, Chunliang LU, Zhuming SUN, Yihui ZHU
Filed: 27 May 21